Drugs / AB598
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05891171 | Oct 2023 → Sep 2027 expected | cancer of unknown primary site, cervical cancer, esophageal cancer, gastric cancer +7 | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05891171 ↗ |
| Route | Intravenous | “Participants will receive AB598 intravenous (IV) infusion once every 3 weeks” NCT05891171 ↗ |